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Background: X-linked agammaglobulinemia is an inherited immunodeﬁciency recognized since 1952. In spite of
seven decades of experience, there is still a limited understanding of regional differences in presentation and
complications. This study was designed by the Primary Immunodeﬁciencies Committee of the World Allergy
Organization to better understand regional needs, challenges and unique patient features.
Methods: A survey instrument was designed by the Primary Immunodeﬁciencies Committee of the World Allergy
Organization to collect both structured and semi-structured data on X-linked agammaglobulinemia. The survey
was sent to 54 centers around the world chosen on the basis of World Allergy Organization participation and/or
registration in the European Society for Immunodeﬁciencies. There were 40 centers that responded, comprising
32 countries.
Results: This study reports on 783 patients from 40 centers around the world. Problems with diagnosis are
highlighted by the reported delays in diagnosis>24 months in 34% of patients and the lack of genetic studies in
39% of centers Two infections exhibited regional variation. Vaccine-associated paralytic poliomyelitis was seen
only in countries with live polio vaccination and two centers reported mycobacteria. High rates of morbidity were
reported. Acute and chronic lung diseases accounted for 41% of the deaths. Unusual complications such as in-
ﬂammatory bowel disease and large granular lymphocyte disease, among others were speciﬁcally enumerated,
and while individually uncommon, they were collectively seen in 20.3% of patients. These data suggest that a
broad range of both inﬂammatory, infectious, and autoimmune conditions can occur in patients. The breadth of
complications and lack of data on management subsequently appeared as a signiﬁcant challenge reported by
centers. Survival above 20 years of age was lowest in Africa (22%) and reached above 70% in Australia, Europe
and the Americas. Centers were asked to report their challenges and responses (n ¼ 116) emphasized the difﬁ-
culties in access to immunoglobulin products (16%) and reﬂected the ongoing need for education of both patients
and referring physicians.
Conclusions: This is the largest study of patients with X-linked agammaglobulinemia and emphasizes the continued
morbidity and mortality of XLA despite progress in diagnosis and treatment. It presents a world view of the
successes and challenges for patients and physicians alike. A pivotal ﬁnding is the need for education of physicians
regarding typical symptoms suggesting a possible diagnosis of X-linked agammaglobulinemia and sharing of best
practices for the less common complications.Introduction
XLA, a primary immunodeﬁciency disorder (XLA OMIM 300755), was
ﬁrst described in 1952 as a congenital agammaglobulinemia. As one of the2ﬁrst recognized inborn errors of immunity, it represents a primary im-
munodeﬁciency with signiﬁcant data on outcomes and clinical features.
The gene affected in XLA, Bruton tyrosine kinase (BTK), was discovered
by two independent groups and is located on X-chromosome (Xq21.3—
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universal B cell deﬁciency (<2%) and absent precursor B cell differenti-
ation in the bone marrow in patients with pathogenic mutations. Lym-
phocytes in their blood and tissues fail to generate plasma cells and have
severely decreased production of all classes of immunoglobulins with
markedly defective antibody responses. B-lineage cells in all organs are
affected resulting in reduced sizes of lymph nodes and tonsils.
The genetic understanding is mature and XLA has been identiﬁed as
the most common cause of agammaglobulinemia. Approximately 85% of
patients with early onset of infections, panhypogammaglobulinemia, and
less than 2% CD19 þ B cells in the peripheral circulation have XLA.3–8
Autosomal recessive agammaglobulinemia has been associated with
mutations in several other genes such as the μ heavy chain gene (IGHM
MIM 601495), λ5 (IGLL1 MIM 146770), Igα (CD79A MIM 112205), Igβ
(CD79B MIM 147245), BLNK (BLNK MIM 613502), PIK3R1 (PIK3R1
MIM 615214), and TCF3 (TCF3 MIM 616941).9,10 Autosomal dominant
agammaglobulinemia was reported as a result of mutations in the
LRRC8A gene on chromosome 9q34 and TCF3 gene on 19p13.3.11,12 The
estimated incidence of XLA ranges from 1:100,000 to 1:200,000 live
births.13–17
Early reports of patients with XLA focused on infection as the most
common presentingmanifestation of XLA.18 Nevertheless, it is not clear if
the speciﬁc infections vary from country to country or region to region. In
a report from Seoul, Korea, recurrent infections observed included
pneumonia, acute otitis media, septic arthritis, skin infection, sepsis,
sinusitis, acute gastroenteritis, cervical lymphadenitis, epididymitis,
meningitis, osteomyelitis, urinary tract infection and encephalitis. One
patient died of hepatocellular carcinoma secondary to hepatitis B virus,
an infection not often reported in North America.19 In Africa, diarrhea
was more common than in European cohorts with nearly half of the
patients with chronic diarrhea.8 Less frequently reported complications
of XLA include neutropenia, usually with Pseudomonas infection at the
time of diagnosis, and the devastating enteroviral meningoencepha-
litis.20,21 Some manifestations may be associated with delay in diagnosis,
however, differences in infection pattern may also be related to regional
variation in exposure.22 A goal of this study was to identify regional
differences in the infection pattern.
With the use of both a patient survey and USIDNET Registry data, 4%
of XLA patients were found to have been diagnosed with Crohn's disease
in the USA.23 Arthritis occurred in 16%, a less frequent feature in Italy
where it was seen in just 10%24 but seen in 29% of XLA patients reported
from China.25 Collectively, the burden of comorbidities impact the
quality of life of patients.26 These country or region-speciﬁc reports
suggest that there may be differences in the clinical features of XLA
around the world.
XLA patients are treated with replacement immunoglobulin and
prophylactic antibiotics to prevent infections.27 Immunoglobulin may be
administered either intravenously (IVIG) or subcutaneously (SCIG) at
intervals of 2–4 weeks for the intravenous route and 1–14 days for the
subcutaneous route. Recently, a new formulation for the administration
of SCIG, using recombinant human hyaluronidase to facilitate the
administration of large volumes of SCIG on a monthly basis has been
developed.28 The adequacy of IgG replacement is determined by the
trough (preinfusion) IgG level in association with the clinical course.
Dose adjustment may be needed for excessive infections, growth, enteric
loss or increased metabolism. In a meta-analysis, pneumonia incidence
declined by 27% with each 100 mg/dL increment in trough IgG and can
be progressively reduced by higher trough IgG levels up to at least
1000 mg/dL.29,30 The frequency of monitoring depends on age (more
frequent monitoring is advisable in younger growing children) and the
clinical considerations of the individual patient.31 The high cost of this
treatment has historically meant that some patients do not receive
appropriate therapy.
Immunoglobulin replacement is one of the most signiﬁcant variables
determining risk of infection, however there are clues that there are other
mechanisms deﬁning the speciﬁc risk proﬁle. BTK has been identiﬁed as3a direct regulator of a key innate inﬂammatory pathway, the NLRP3
inﬂammasome, and NK cell activation.32,33 It is essential for normal
TLR-induced IL-10 production in macrophages.34 Other innate functions
of BTK have been invoked to explain the unique susceptibility to en-
teroviruses, however, these data are controversial.35–38 The impact of the
defective BTK protein is not fully deﬁned but patients exhibit higher than
expected rates of inﬂammatory diseases suggesting dysregulation of the
innate immune response.23 Interactions of the dysregulated innate im-
mune response with colonizing microbes is possible but not yet deﬁned
speciﬁcally for XLA.39,40
There are multiple potential differences in infectious exposures/
microbiome, and perhaps differences in diagnostic approaches and care
delivery. Hence, we undertook this survey to understand the diversity of
approaches and clinical features in XLA around the world and to call
attention to the main management challenges based on a proposal
developed by the Primary Immunodeﬁciencies Committee of the World
Allergy Organization (WAO).
Methods
This study was designed and formulated by the WAO Primary Im-
munodeﬁciencies committee in 2018 to understand challenges and
strengths around the world in the diagnosis and management of XLA. A
structured survey instrument was developed and sent to 54 immunology
centers around the world deﬁned by participation in the WAO and/or
registration with the European Society for Immunodeﬁciencies. One
center had no XLA patients, and in three cases contact information was
incorrect. Ten centers did not respond. Forty survey instruments were
collected and analyzed using Prism (GraphPad, La Jolla, California).
Percents of respondents are generally reported. Fig. 1 displays the loca-
tion of the centers participating in this survey. Aggregate data was re-
ported from each center and the Children's Hospital of Philadelphia
Institutional Review Board determined that such data reported in
aggregate did not require consent. The deﬁnition of XLA was performed
at each center and utilized the ESID criteria.41
The survey instrument included questions on the features of the
centers (health coverage system, the age of the center and the number of
living patients followed up), questions relevant to diagnosis (mode of
diagnosis and diagnosis lag) and treatment modalities. We speciﬁcally
queried for cases of inﬂammatory bowel disease, enteroviral disease,
large granular lymphocyte disease, arthritis, chronic cutaneous ulcers
(usually due to Campylobacter43) and vaccine-associated paralytic polio.
We also offered a free text option for other unique and unusual mani-
festations”. Inquiry was made on the average life span, survival above 20
years of age and the cause of death. This study speciﬁcally asked centers
to delineate their main management challenges. Centers were allowed to
list up to three challenges. The challenges were grouped according to the
content of the free text.
Results
Characteristics of reporting centers
Data were collected from 40 centers representing 32 countries
(Table 1). We asked three questions to understand the care delivery
model across the countries: insurance/health coverage, the age of the
center and how many living XLA patients are followed at each center.
Healthcare coverage was largely skewed towards government coverage:
54% of centers reported comprehensive coverage, 27% reported some
government coverage, 7% reported private insurance and 7% reported
self-pay. As expected, there was heterogeneity in size and age of the
centers although 90% of the centers have been following patients for
over ten years, supporting the concept that immunodeﬁciency is a
maturing specialty (Table 2). These descriptive data provide a landscape
for understanding healthcare as it relates to the care of patients with
XLA.
Fig. 1. A world map is displayed with the approximate locations of the reporting centers indicated with asterisks.
Table 1
Recruitment locations and distribution.
Continent Country Number of centers
Europe Belgium 1
Czech Republic 1
Finland 1
Italy 4
Northern Ireland 1
Portugal 1
Russia 1
Spain 1
Ukraine 1
Subtotal 12
North America Canada 1
Mexico 1
USA 3
Subtotal 5
South America Argentina 1
Brazil 2
Chile 1
Peru 1
Subtotal 5
Asia China (Hong Kong) 1
India 2
Iran 1
Japan 1
Kuwait 1
Lebanon 1
Malaysia 1
Pakistan 1
Turkey 1
Subtotal 10
Africa Algeria 1
Egypt 2
Morocco 1
South Africa 1
Sudan 1
Tunisia 1
Subtotal 7
Australia Australia 1
Subtotal 1
TOTALS 32 40
Table 2
Center characteristics.
Percentage of centers
Mean follow-up time of patients with XLA
<5 years 2%
6–10 years 7%
>10 years 90%
Number of living patients with XLA
0-5 patients 36%
6-10 patients 19%
11-15 patients 10%
>15 patients 36%
Table 3
Diagnostic and treatment methods.
Percentage of
centers (%)
Diagnostic method Clinical history and serum
immunoglobulins
0
Clinical history, serum
immunoglobulins and ﬂow
cytometry
39
Clinical history, serum
immunoglobulins, ﬂow cytometry
and molecular studies.
61
Delay between symptoms
and diagnosis
<12 months 32
13–24 months 34
25–36 months 17
>36 months 17
Main treatment strategy Antibiotics for acute infections as
the only treatment
2
Prophylactic antibiotics without
Immunoglobulin replacement
0
Immunoglobulin replacement 98
Hematopoietic stem cell
transplantation
0
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4Diagnosis and management options
Four questions established the mode of diagnosis at each center and
the treatments most frequently utilized (Table 3). All centers used ﬂow
Table 6
Challenges.
Challenge Percent of responses
N ¼ 116
Access to immunoglobulin 16%
Delay in diagnosis/Access to diagnostic tests/Awareness 16%
Compliance 14%
Access to subcutaneous immunoglobulin 7%
Pathogen detection and therapy for speciﬁc pathogen 7%
Transitioning to adult providers 6%
Financial burden 5%
Enteroviral infections 3%
Psychological support 3%
Z.A. El-Sayed et al. World Allergy Organization Journal 12 (2019) 100018cytometry for diagnosis but genetic testing was widely utilized as well (in
61% of centers). The lag from the time of ﬁrst complaint to diagnosis
varied widely with 34% of centers reporting delays of more than 24
months. The delay was not related to type of health insurance coverage
(ANOVA analysis not signiﬁcant). Nearly all centers (98%) utilized
immunoglobulin replacement as their main treatment, however access to
subcutaneous immunoglobulin (SCIG) was reported by only 61% of
centers.
Survival
Most centers (78%) reported that patients with XLA had a good sur-
vival rate with an average life span of over 15 years of age, however, only
62% of centers who saw adults reported that>75% of their patients with
XLA survived beyond 20 years of age. The causes of death were highly
varied. Eleven centers reported no deaths. There were 46 causes of death
reported. Among the listed causes, chronic lung disease or acute lung
disease were the most common 19/46 (41%). Sepsis was listed for six
deaths (13%). There were six deaths from CNS infection/enterovirus
(13%). Two patients had colitis listed as a cause of death. The remainder
of the distinct causes were listed only once (cachexia with concomitant
TIMM8A deletion, aneurysm, stomach cancer, hepatitis C, among
others). When we assessed regional effects on survival, there were clear
differences by continent (Table 4).
Unusual complications
This large cohort of patients with XLA allowed us to deﬁne the fre-
quencies of complications previously reported in small series or case
reports and to explore whether there is regional variation (inﬂammatory
bowel disease, enteroviral disease, large granular lymphocyte disease,
arthritis, chronic cutaneous ulcers (usually due to Campylobacter42) andTable 4
Regional differences in XLA.
Survival
>20y
of agea
Enteroviral
meningoencephalitis
Inﬂammatory
bowel disease
Arthritis
Africa n ¼ 229 22% 1.3% 1.3% 8.3%
Asia n ¼ 169 39% 0.59% 2.4% 6.5%
Australia n ¼ 7 >75% 0 0 14.3%
Europe n ¼ 186 >75% 0.54% 5.9% 17.2%
North America
n ¼ 136
75% 0 2.2% 2.9%
South America
n ¼ 56
72% 10.7% 8.9% 7.1%
a Survival was based on a weighted average of reported categorical responses.
Table 5
Infrequent manifestations of XLA.
Complication Cases
reported
Percentage
of reported
cohort
N ¼ 783
Data from
other
publications8,14,18,19,24,25,43–52
Inﬂammatory bowel
disease
27 3.4% 2.27%
Enteroviral
meningoencephalitis
36 4.6% 4–38%a
Large granular
lymphocyte disease
1 0.1% –
Arthritis 62 7.9% 7–29%
Chronic cutaneous
ulcers
6 0.8% 6–28%b
Vaccine-associated
paralytic polio
12 1.5% 3%
1%
a Meningitis/encephalitis. Could be enteroviral disease, bacterial meningitis or
autoimmune conditions.
b Reported as skin involvement.
5vaccine-associated paralytic polio). We also offered a free text option for
other unusual manifestations. There were 12 occurrences of
vaccine-associated paralytic poliomyelitis with only one reported from
Europe and none from North America (Table 4). There were 62 cases of
arthritis and 10 of those were from Russia, a signiﬁcant enrichment.
Otherwise, there was no clear evidence of regional variation. (Table 5).
Among the free text listings, none were listed more than once. Nor-
ovirus, campylobacter, and hepatitis C were each listed once as speciﬁc
infections. Conjunctivitis, autoimmune enteropathy, cholangitis, auto-
immune hemolytic anemia, and sarcoid were each listed once as in-
ﬂammatory conditions.
Challenges reported by centers
We recognized that each center could have unique aspects related to
patient care that were not predictable and we offered centers the op-
portunity to deﬁne their biggest challenges and unique patient features
using a free text response (Table 6). Regionally unique aspects of care
included mycobacterial infections in Argentina and India and vaccine-
associated paralytic polio in countries that use the live polio vaccine
(Table 4). The challenges were grouped according to the content of the
free text. Centers were allowed to list up to three challenges. Immuno-
globulin access, awareness of XLA/delay in diagnosis/diagnostic test
access were the most common concerns listed at 16% of total responses
each. Six centers listed cost to the patient as prohibitive or limiting. These
centers were located in countries with incomplete government coverage
and were located in North America, Asia, and Africa. Other common
responses were compliance, quality of life issues and transition of care.
Enteroviral infections, inﬂammatory diseases, conjunctivitis and man-
agement of lung disease were listed by at least two centers. These con-
cerns ranged from pragmatic aspects of patient care such as management
of rare complications, to pleases for improved education regarding
recognition of XLA, to government policy regarding immunoglobulin.
Discussion
To understand the current landscape of regional variation in XLA, we
performed a survey to understand diagnostic approaches, available
therapies and regional complications. This WAO survey achieved a
remarkable reportage from 32 countries widely distributed around the
world. This is the largest series of XLA patients reported to date. We
compared our data to published series of patients with XLA (Table 7).8,14,
18,19,24,25,43–52 Notable differences across reports were the frequency of
neutropenia ranging from 1 to 22% among those who reported this
feature. Meningoencephalitis was reported in 4–38% of patients at
different centers although pathogens were rarely reported. Therefore,
these could have represented enteroviral disease, bacterial meningitis or
autoimmune conditions. Our survey identiﬁed enteroviral disease in
4.6% of patients consistent with that seen in other reports. Arthritis was
reported in our survey in 7.9% while it was reported form other centers
as 7–29%. Orchitis, an unusual clinical feature in XLA, was reported in
signiﬁcant numbers from two centers and was not speciﬁcally queried in
our survey. Thus, the data from this survey are consistent with previous
Table 7
Analysis of published case series of patients with XLA.
Country
(Reference)
(N) Age
-presentation
Age at
diagnosis
Presenting
manifestation
FH Pneumonia (%) GI disease (%) Meningitis/
encephalitis
Otitis Other CLD (%) Deaths (%) BTK
mutations
Algeria44 9 15 m 6.7y 100% Respiratory
infections
22% 100% 22% 22% Neutropenia
11% Arthritis
11% Skin infection
77% 66.6%
Iran45,46 30 67% 27% 20% 63% 20%
Septic arthritis
13% JIA
10%
Neutropenia
17%
Morocco8 50 10 m 4y 32% 92% 42% 27% 47% 37% arthritis
10% osteomyelitis
15% 79%
France47 31 7 m 84% Infections 16% 48% 10%
Enteropathy
10% Enteroviral 13% Chronic sinusitis
3% Orchitis
3% Septic Arthritis
22%
Aseptic arthritis
6% Skin
19% 3.2% 83.8%
Italy24 73 3.5y 68%
Respiratory infections
40% 53% 19%
Gastroenteritis
4% 50% 48% Chronic sinusitis
27% Skin
10% Arthritis
3% VAPP
1% Neutropenia
33% 1.4% 100%
Netherlands48 15 14 m 6.5y 100% 73% Gastroenteritis
47% Giardiasis
27% 53% 67% Sinusitis 80% 33% 26.6%
Poland43 44 13 m 3.7y 73%
Lower respiratory
infections
59% 64% 14% 41% 34% Sinusitis
16% Arthritis
14%
Skin abscesses
27% 4.5% 100%
Portugal49 9 13 m 3.4y 89%
Infection
11% 56% 33% Giardia 78% 33% Neutropenia
22% Septic arthritis
22% 0% 100%
Spain50 30 23 m 6y 55% 83%
United Kingdom51 69 2.2y 62% 67% 16% 17% 17% Skin
6% Septic arthritis
16%
Aseptic arthritis
China25 62 24 m 7y 40% 73% 29% 13% 37% 29% arthritis
3% vaccine-associated polio
100%
Korea19 19 4.9y 31% 68% 16% Gastroenteritis 16%
Meningitis
5%
Encephalitis
32% 26% Septic arthritis
26% Skin Infection
21% Sinusitis
5% 10.5% 42%
Mexico52 26 69% 19% Diarrhea
4% Colitis
38% 61% 57% Sinusitis
38% Septic arthritis
11% Skin abscesses
100%
USA18 96 10 m 2.9y 65%
Lower Respiratory
75% ENT
55% 65% 35% 16% 59% 28% Skin 70% 17%
USA14 201 12 m 4y 86% Infection 58% 62% 23% 12% 70% 60% Sinusitis
8% Orchitis
18% Skin
11% Neutropenia
7% Septic arthritis
1% VAPP
8.5% 59%
FH: Family history; GI: gastrointestinal; CLD: chronic lung disease; JIA: juvenile idiopathic arthritis; VAPP: vaccine associated paralytic poliomyelitis.
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patients with XLA.
Infections are a major clinical indicator of XLA. The original
description by Colonel Ogden Bruton depicted a boy with recurrent
sepsis, pneumonia and otitis media.53,54 Respiratory tract infections
constitute a prominent and ongoing clinical problem despite immuno-
globulin replacement therapy. In one study, the overall probability of
developing chronic lung disease reached about 80% after 17 years of
follow-up.24 Gastrointestinal disorders, mainly diarrhea were reported
almost as often as lower respiratory tract infections in Poland whereas
inﬂammatory bowel disease was diagnosed quite infrequently.43 In India,
the most common infection noted was pneumonia.55 The summary of
features frommany countries in Table 7 highlights the continuing pattern
of signiﬁcant and life-altering infections. Chronic lung disease and sepsis
were the two most common causes of death, in this survey, suggesting
that management continues to fall short for some patients. Nevertheless,
there is cause for cautious optimism as nearly all centers had access to
immunoglobulin even if access was complicated and gaps occurred. Over
half of the centers reported that the majority of their patients were
reaching adulthood.
Patient survival was highly regional, reﬂecting healthcare challenges
in countries with emerging economies. Several centers commented on
the difﬁcult logistics for patients with only a single center in some
countries offering diagnosis and treatment. The Eurodis survey noted
patients with rare diseases lack access to local care in many European
countries.56 Improving education of the primary care physicians man-
aging patients locally was a key need noted by several contributors. Ef-
forts to provide printed materials in various languages could beneﬁt
many patients and increasing use of technology to support primary care
physicians will be increasingly important. Lack of education is also
related to delays in diagnosis. When primary care providers understand
the clinical features they are more likely to refer for diagnostic testing.57
Although a number of efforts have been instituted to improve awareness
and recognition of inborn errors of immunity, it appears that additional
efforts could have a substantial beneﬁt.58
This study examined uncommon complications, leveraging the large
sample size and the expertise of the contributors. In this regard, we were
able to identify a higher than anticipated frequency of these complica-
tions collectively. Enteroviral disease,20 including vaccine-associated
paralytic polio is still occurring (12 patients). This ruinous complica-
tion is possibly related to delayed diagnosis.20 Whereas inﬂammatory
bowel disease was diagnosed quite infrequently (1/44 (2.3%) in one
center43), this study showed a frequency of 3.4%. Complications such as
cutaneous ulcers (often due to Flexispira or Campylobacter), inﬂammatory
bowel disease, large granular lymphocyte disease and arthritis are not
thought to be related to lack of treatment, although the speciﬁc risks for
these infrequent complications are not known.23,42,59 Mycoplasma or
Ureaplasma arthritis may occur more often in untreated or sub-optimally
treated patients.60–62 The overwhelming sense from this survey is that
these “infrequent” complications collectively affect a signiﬁcant number
of patients with XLA. Nearly 20% of patients had one of these “infre-
quent” complications. In the free text ﬁelds, centers noted struggles to
treat unusual infections, unusual autoimmunity, and to coordinate mul-
tiple specialties for complex patients. These challenges are universal and
not clearly related to geography, type of insurance, or size of the center.
Our ﬁndings support development of a world-wide community of im-
munologists to share best practices for rare complications.
Our overall goal was to examine regional differences in diagnostic
testing, therapies, and clinical manifestations. In fact, we uncovered
relatively few regional differences with vaccine-associated paralytic
polio being perhaps the only complication with a clear regional compo-
nent, wholly related to exposure. Mycobacterial infections also seemed to
have a regional effect.
We offered respondents the opportunity to describe their main chal-
lenges and many responses were not purely medical. Compliance with
medications, transitioning of patients to adult providers and education of7patients ranked very high among the cited challenges in our survey. As
centers move from the original concern of keeping patients alive, now the
focus has ﬁttingly moved to optimization of health. These concerns were
surprising because they require time and focus but little in the way of
technology or other resources that are often limiting. There are few
guidelines for the transitioning speciﬁcally for people living with inborn
errors of immunity.63 Some progress has been made in developing
guidelines for transitioning of children with chronic illness and these
may be applied, although a destination adult-care clinic is still central to
the process64,65 and often lacking.
Limitations of this study are the use of a non-validated survey in-
strument that was focused on speciﬁc outcomes and questions. The ag-
gregations of the free text responses may have imposed an interpretation
not been intended by the responder. Additionally, this survey did not
reach every country. There is likely additional heterogeneity in responses
not captured in this survey. Representation from East Asia was relatively
weak and Southern Africa was represented by a single center. Never-
theless, this study provides an important framework for strategically
considering diagnostic testing and treatment approaches that could be
mandated by the World Health Organization. The World Health Orga-
nization already includes immunoglobulin as an “Essential Medica-
tion”.66 This is the largest cohort of patients with XLA ever reported and
provides critical information on medical concerns as well as challenges to
meeting the next goal of a full and healthy life for all patients.
In summary, this survey conceptualized by the WAO in 2018,
demonstrated key ﬁndings. Most patients are surviving to adulthood and
infections continue to be the most frequent manifestation. Access to
immunoglobulin replacement is fairly uniform but centers reported
frustrations with lack of subcutaneous immunoglobulin, the high cost of
immunoglobulin and the logistical aspects of obtaining and delivering
immunoglobulin. This survey highlighted the less frequent complications
and supports development of a multinational registry or communal
blackboard to share treatment approaches and to study outcomes. Stra-
tegies to share practices on transitioning and education of primary care
and other referral sources is a critical need and one in which resource
sharing could be beneﬁcial.
Conclusions
Survival of patients with XLA is good globally, however, this study
revealed a surprising burden of morbidities with nearly 20% suffering
from what have been considered unusual complications. Centers identi-
ﬁed a number of challenges in providing care for patients including ac-
cess to immunoglobulin in a manner that is ﬁnancially achievable,
logistically feasible, and respectful of patients' time. Other challenges
included education of patients and primary care physicians and the
transitioning of patients to adult centers. Overall, this study supports
better efforts to share best practices internationally, and suggests that
there is much to be done to optimize patient care.
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